SRR1474795
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR602131 | GTEX | — | 0.960 |
| 2 | SRR1369219 | GTEX | — | 0.959 |
| 3 | SRR1335446 | GTEX | — | 0.955 |
| 4 | SRR1382869 | GTEX | — | 0.949 |
| 5 | SRR1335047 | GTEX | — | 0.948 |
| 6 | SRR608598 | GTEX | — | 0.946 |
| 7 | SRR615020 | GTEX | — | 0.945 |
| 8 | SRR1077405 | GTEX | — | 0.943 |
| 9 | SRR1358561 | GTEX | — | 0.942 |
| 10 | SRR818270 | GTEX | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.481 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.476 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.446 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.432 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.382 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.371 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.354 | Inavolisib | — uncovered |
| COAGULATION | 0.339 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.331 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.298 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.265 | Inavolisib | — uncovered |
| COMPLEMENT | 0.254 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.251 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.243 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.214 | Inavolisib | — uncovered |
| APOPTOSIS | 0.145 | Idelalisib | — uncovered |
| MYOGENESIS | 0.071 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.039 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.025 | Inavolisib | — uncovered |
| HYPOXIA | 0.006 | Idelalisib | — uncovered |